iPSC-derived RPE/PLGA transplantation

Asset

Replaces damaged retinal pigment epithelium with autologous induced pluripotent stem cell-derived cells on a biodegradable scaffold.

Stage
Phase 1
Modality
Cell therapy
Target
Not known
2
Indications
1
Trial
1
Developer

Trial NCT04339764 is still running. Trial NCT04339764 updated in its registry on Nov 12, 2026. clinicaltrials.gov

Indications

2

In the full profile

  • Owner and partners1
  • Trials1
  • Competitors5

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets